Federal award (DELIVERY ORDER, fiscal year 2021)
Recipient: THE INSTITUTE FOR CANCER RESEARCH
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2022-06-15 to 2023-12-14
Current total value of award: $614163
Description: BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM:  PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERS  TASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIATED COLORECTAL CANCER IMMUNOPREVENTION